Supernus Shows Rapid Response in Phase 2a Trial of Depression Drug SPN-820

Supernus Pharmaceuticals has reported encouraging results from its Phase 2a trial of the depression drug SPN-820, showcasing its potential as a fast-acting treatment for major depressive disorder (MDD). In this open-label study involving 40 adults, participants experienced rapid and significant improvements in depressive symptoms. Specifically, there was a 6.1-point reduction in the HAM-D6 depression scale within two hours, which deepened to 9.6 points by Day 10[1]. Similarly, MADRS scores decreased by 16.6 points in just four hours, reaching 22.9 points by Day 10[2]. The treatment was generally well-tolerated, with mild adverse events such as headaches and nausea, supporting its safety profile for further trials[2].